Fremont, CA (PRWEB) April 3, 2010
Optovue, a pioneer in fourier/spectral-domain optical coherence tomography (OCT), has announced a milestone in shipping serial number 2000 of the RTVue fourier/spectral-domain OCT system at the end of February. Optovue also announced that it has shipped the first 100 iVue compact SD-OCT systems against initial international orders of more than 200 in the first 60 days since the January launch. The iVue compact advanced OCT is currently only available in specific countries outside the United States.
RTVue is already one of the most versatile - and among the fastest Fourier-domain (also called spectral domain) OCTs on the market, with an imaging speed of 26,000 full-resolution* axial scans per second. The first FDA cleared advanced OCT was also the first FDA cleared SD-OCT for imaging both the front and back of the eye. The revolution that started with RTVue is continuing with the latest in the company portfolio - the iVue – which was released for export outside the US and began shipping in January 2010. The iVue includes scanning and reports for retina, optic nerve and cornea imaging as standard in a compact advanced OCT system.
*Some OCT systems utilize only half of the pixels available in the line scan camera used in these SD-OCT systems. This results in near doubling of the "claimed" speed, but each single scan contains only half the available resolution.
About RTVue and iVue
RTVue is the first Fourier domain (also known as spectral domain) OCT to be introduced in the United States, and is the only OCT that is cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, producing extremely high definition images with more biological detail and functional advantages than the previous technology.
About Optovue (http://www.optovue.com)
Optovue Corp. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with European operations in Heidelberg, Germany.
# # #